Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study

Retrospective cohort study (n=949) found improved overall survival for hypomethylating agents vs hydroxyurea (20.7 s 15.6 months, HR 1.39, 95%CI 1.17-1.65) and intensive chemotherapy (20.7 vs 14.0 months, 1.55, 1.16-2.05). But no advantage was found in lower-risk disease.

The Lancet Haematology